VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Stock Comparison

CSL Limited vs Danaher Corporation

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

CSL Limited

CSL · ASX

Market cap (USD)$74.4B
Gross margin (TTM)48.9%
Operating margin (TTM)23.3%
Net margin (TTM)14.9%
SectorHealthcare
IndustryBiotechnology
CountryAU
Data as of2026-01-02
Moat score
77/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into CSL Limited's moat claims, evidence, and risks.

View CSL analysis

Danaher Corporation

DHR · New York Stock Exchange

Market cap (USD)$148.1B
Gross margin (TTM)60.9%
Operating margin (TTM)20.9%
Net margin (TTM)14.7%
SectorHealthcare
IndustryMedical - Diagnostics & Research
CountryUS
Data as of2025-12-22
Moat score
77/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Danaher Corporation's moat claims, evidence, and risks.

View DHR analysis

Comparison highlights

  • Moat score: both at 77 / 100.
  • Segment focus: CSL Limited has 3 segments (71.7% in CSL Behring); Danaher Corporation has 3 segments (41% in Diagnostics).
  • Moat breadth: CSL Limited has 7 moat types across 3 domains; Danaher Corporation has 7 across 3.

Primary market context

CSL Limited

CSL Behring

Market

Plasma-derived therapies (immunoglobulins, albumin, coagulation factors) plus recombinant and gene therapies for rare and serious diseases

Geography

Global

Customer

Hospitals, specialty pharmacies, physicians; payers and national health systems

Role

Vertically integrated biopharma (plasma collection -> fractionation/manufacturing -> commercial distribution)

Revenue share

71.7%

Danaher Corporation

Diagnostics

Market

In vitro diagnostics instruments, consumables, software and services (clinical lab, acute care/POC, pathology, molecular diagnostics)

Geography

Global

Customer

Hospitals, physician offices, reference laboratories, pathology labs, critical care settings

Role

IVD device manufacturer and reagent/test supplier + software/services

Revenue share

41%

Side-by-side metrics

CSL Limited
Danaher Corporation
Ticker / Exchange
CSL - ASX
DHR - New York Stock Exchange
Market cap (USD)
$74.4B
$148.1B
Gross margin (TTM)
48.9%
60.9%
Operating margin (TTM)
23.3%
20.9%
Net margin (TTM)
14.9%
14.7%
Sector
Healthcare
Healthcare
Industry
Biotechnology
Medical - Diagnostics & Research
HQ country
AU
US
Primary segment
CSL Behring
Diagnostics
Market structure
Oligopoly
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
77 / 100
77 / 100
Moat domains
Supply, Legal, Demand
Demand, Supply, Legal
Last update
2026-01-02
2025-12-22

Moat coverage

Shared moat types

Operational ExcellenceRegulated Standards Pipe

CSL Limited strengths

Supply Chain ControlPhysical Network DensityGovernment Contracting RelationshipsCapacity MoatProcurement Inertia

Danaher Corporation strengths

Installed Base ConsumablesDesign In QualificationService Field NetworkLearning Curve YieldSuite Bundling

Segment mix

CSL Limited segments

Full profile >

CSL Behring

Oligopoly

71.7%

CSL Seqirus

Oligopoly

13.9%

CSL Vifor

Oligopoly

14.4%

Danaher Corporation segments

Full profile >

Biotechnology

Oligopoly

28.3%

Life Sciences

Oligopoly

30.7%

Diagnostics

Oligopoly

41%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.